top of page
We're enrolling in the following studies
Respiratory Syncytial Virus (RSV) Treatment Study - 2025
​
A potential new treatment for adults, aged 18 and older, with a new diagnosis of RSV who are at high risk of progression to severe disease.
​
SARS-CoV-2 (Covid-19) Treatment Study - 2025
​
A potential new treatment for adults, aged 18 or older, with a new diagnosis of Covid-19 who are at high risk for disease progression.
​
Contact us
bottom of page